Ensayos clínicos

887 ensayos encontrados

CompletadoFase 3ClinicalTrials.gov

A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Phase 3 Study of Baricitinib in Patients With COVID-19 Infection

IntervencionalInicio: 12 de jun de 2020ID: NCT04421027

DesconocidoFase 3ClinicalTrials.gov

A Randomized, Double-Blind, Equivalence Trial Comparing Emtricitabine to Stavudine Within a Triple Drug Combination Containing Didanosine Plus Efavirenz in Antiretroviral-Drug Naive HIV-1 Infected Patients

IntervencionalInicio: 1 de ago de 2000ID: NCT00006208

CompletadoFase 3ClinicalTrials.gov

A Phase III, Randomized, Multicenter, Double Blind, Double-Dummy, Parallel-Group, Comparative Study to Determine the Efficacy, Safety, and Tolerability of Ceftazidime Avibactam Plus Metronidazole Versus Meropenem in the Treatment of Complicated Intra-Abdominal Infections In Hospitalized Adults

IntervencionalInicio: 1 de mar de 2012ID: NCT01499290

CompletadoFase 3ClinicalTrials.gov

An Open-Label, Randomized, Multicenter, Phase III Study of Ceftazidime Avibactam (CAZ-AVI, Formerly CAZ104) and Best Available Therapy for the Treatment of Infections Due to Ceftazidime Resistant Gram Negative Pathogens

IntervencionalInicio: 1 de ene de 2013ID: NCT01644643

Activo, no reclutaFase 3ClinicalTrials.gov

Estudio multicéntrico, doble ciego, controlado con placebo, de retirada aleatoria y extensión abierta seguido de ciclos de tratamiento abierto a largo plazo para evaluar la eficacia, seguridad y tolerabilidad de remibrutinib (LOU064) en pacientes adultos con urticaria crónica espontánea que completaron los estudios de fase 3 anteriores con remibrutinib

IntervencionalInicio: 9 de dic de 2022ID: NCT05513001

Activo, no reclutaFase 3ClinicalTrials.gov

Estudio de fase 3, aleatorizado, doble ciego, controlado activo para evaluar el cambio a un régimen oral semanal de islatravir/lenacapavir en personas con VIH-1 con supresión virológica en bictegravir/emtricitabina/tenofovir alafenamida (B/F/TAF)

IntervencionalInicio: 9 de oct de 2024ID: NCT06630286

CompletadoFase 4ClinicalTrials.gov

An International, Multi-Center Study Evaluating the Correlation of IL28B Genotypes With Patient Demographics and Disease Characteristics in Patients With Chronic Hepatitis C

IntervencionalInicio: 1 de ago de 2011ID: NCT01675427

ReclutandoFase 3ClinicalTrials.gov

Estudio fase 3, doble ciego, de 2 brazos, de eficacia y seguridad para investigar fosmanogepix IV seguido de fosmanogepix oral frente a caspofungina IV seguida de fluconazol oral en participantes adultos con candidemia y/o candidiasis invasiva

IntervencionalInicio: 11 de dic de 2024ID: NCT05421858

CompletadoFase 3ClinicalTrials.gov

A Phase 3 Study of 2 Dose Regimens of Telaprevir in Combination With Peginterferon Alfa-2a (Pegasys®) and Ribavirin (Copegus®) in Treatment-Naive Subjects With Genotype 1 Chronic Hepatitis C

IntervencionalInicio: 1 de mar de 2008ID: NCT00627926

ReclutandoFase 2ClinicalTrials.gov

Estudio prospectivo multicéntrico (B-Sure) para evaluar la durabilidad a largo plazo de la respuesta al tratamiento en participantes con hepatitis B crónica con y sin terapia con análogos de nucleós(t)idos que hayan participado en un estudio previo de tratamiento con bepirovirsen

IntervencionalInicio: 14 de dic de 2021ID: NCT04954859

CompletadoFase 3ClinicalTrials.gov

A Phase 3, Multicenter, Randomized, Double-blind Study of the Efficacy and Safety of Rezafungin for Injection vs. Intravenous Caspofungin Followed by Oral Fluconazole Step Down in the Treatment of Subjects With Candidemia and/or Invasive Candidiasis

IntervencionalInicio: 7 de oct de 2018ID: NCT03667690

TerminadoFase 3ClinicalTrials.gov

A Double-blind, Randomized, Placebo-controlled Study to Assess the Safety and Efficacy of Nebulized PC945 When Added to Systemic Antifungal Therapy for the Treatment of Refractory Invasive Pulmonary Aspergillosis (OPERA-T Study)

IntervencionalInicio: 14 de jun de 2022ID: NCT05238116

CompletadoFase 2ClinicalTrials.gov

An Open-label Clinical Trial Phase IIB to Evaluate the Immunogenicity and Safety of Recombinant Novel Coronavirus Vaccine in Participants Aged 18 Years and Above That Previously Received One Dose of Sputnik V

IntervencionalInicio: 1 de oct de 2021ID: NCT05293223

CompletadoFase 3ClinicalTrials.gov

Ensayo clínico de fase III, multicéntrico global, aleatorizado, doble ciego, controlado con placebo, con diseño adaptativo, para evaluar la eficacia, seguridad e inmunogenicidad de Ad5-nCoV en adultos de 18 años de edad y mayores

IntervencionalInicio: 15 de sept de 2020ID: NCT04526990

CompletadoFase 3ClinicalTrials.gov

A Phase 3, Open-Label Study With Asunaprevir and Daclatasvir Plus Peginterferon Alfa-2a (Pegasys) and Ribavirin (Copegus) (P/R) (QUAD) for Subjects Who Are Null or Partial Responders to Peginterferon Alfa 2a or 2b Plus Ribavirin With Chronic Hepatitis C Genotypes 1 or 4 Infection

IntervencionalInicio: 1 de may de 2012ID: NCT01573351

CompletadoFase 3ClinicalTrials.gov

Immunogenicity Study of the Antibody Persistence and Booster Effect of PENTAXIM™ at 18 Months of Age Following a Primary Series of DTaP-IPV-HB-PRP~T Combined Vaccine or of PENTAXIM™ and ENGERIX B® PEDIATRICO at 2, 4, and 6 Months of Age in Healthy Argentinean Infants

IntervencionalInicio: 1 de feb de 2006ID: NCT00303316

CompletadoFase 2ClinicalTrials.gov

Estudio de fase 2b aleatorizado, doble ciego, controlado con placebo y multicéntrico para evaluar la eficacia, la seguridad y la tolerabilidad de AZD2693 en participantes con esteatohepatitis no alcohólica (EHNA) no cirrótica con fibrosis que son portadores del alelo de riesgo PNPLA3 rs738409 148M

IntervencionalInicio: 15 de mar de 2023ID: NCT05809934

CompletadoFase 2ClinicalTrials.gov

A Randomized, Open-Label, Phase II Study of Subcutaneous Interleukin-2 (Proleukin) Plus Antiretroviral Therapy vs. Antiretroviral Therapy Alone in Patients With HIV Infection and at Least 350 CD4+ Cells/mm3

IntervencionalInicio: 1 de oct de 1997ID: NCT00000889

TerminadoFase 3ClinicalTrials.gov

A Phase 3, Multicenter, Randomized, Double-blind, Controlled Study to Evaluate the Efficacy and Safety of Peramivir Administered Intravenously in Addition to Standard of Care Compared to Standard of Care Alone in Adults and Adolescents Who Are Hospitalized Due to Serious Influenza

IntervencionalInicio: 1 de nov de 2009ID: NCT00958776

CompletadoFase 3ClinicalTrials.gov

A PHASE 3, RANDOMIZED, OBSERVER-BLINDED STUDY TO EVALUATE THE EFFICACY, SAFETY, TOLERABILITY, AND IMMUNOGENICITY OF A MODIFIED RNA VACCINE AGAINST INFLUENZA COMPARED TO LICENSED INACTIVATED INFLUENZA VACCINE IN HEALTHY ADULTS 18 YEARS OF AGE OR OLDER

IntervencionalInicio: 12 de sept de 2022ID: NCT05540522